Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 533 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Dr. Mihael Polymeropoulos est le Chairman of the Board de Vanda Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2003.
Quelle est la performance du prix de l'action VNDA ?
Le prix actuel de VNDA est de $6.88, il a augmenté de 0.72% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Vanda Pharmaceuticals Inc ?
Vanda Pharmaceuticals Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Vanda Pharmaceuticals Inc ?
La capitalisation boursière actuelle de Vanda Pharmaceuticals Inc est de $407.2M
Est-ce que Vanda Pharmaceuticals Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 7 analystes ont établi des notations d'analystes pour Vanda Pharmaceuticals Inc, y compris 2 achat fort, 5 achat, 2 maintien, 0 vente et 2 vente forte
